FDA filing of aclidinium bromide/formoterol fumarate delayed.
Forest Laboratories, and Almirall will delay the planned fourth quarter 2013 submission of a New Drug Application for the combination of aclidinium bromide, a long acting muscarinic antagonist and formoterol fumarate, a long acting beta agonist, for the indication of Chronic Obstructive Pulmonary Disease .
This decision was based on comments provided by the FDA at a recent pre-NDA meeting. The delay is related to resolving chemistry, manufacturing and control specifications associated with the combination formulation.
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma